XML 103 R91.htm IDEA: XBRL DOCUMENT
v3.21.2

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 2,100 | $ 1,664 | $ 4,127 | $ 3,676
Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 938 | 785 | 1,834 | 1,724
Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 470 | 262 | 924 | 654
OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 363 | 317 | 706 | 666
Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 305 | 273 | 615 | 579
Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 24 | 27 | 48 | 53
Bausch + Lomb |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 934 | 677 | 1,815 | 1,552
Bausch + Lomb | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 134 | 96 | 259 | 234
Bausch + Lomb | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 397 | 220 | 779 | 561
Bausch + Lomb | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 329 | 295 | 645 | 616
Bausch + Lomb | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 68 | 57 | 119 | 125
Bausch + Lomb | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 6 | 9 | 13 | 16
Salix |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 516 | 404 | 988 | 881
Salix | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 514 | 403 | 984 | 880
Salix | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 1 | 4 | 1
International Rx |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 313 | 249 | 619 | 540
International Rx | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 67 | 55 | 126 | 121
International Rx | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
International Rx | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 32 | 20 | 57 | 46
International Rx | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 206 | 161 | 418 | 349
International Rx | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 8 | 13 | 18 | 24
Ortho Dermatologics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 137 | 117 | 278 | 248
Ortho Dermatologics | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 59 | 70 | 124 | 146
Ortho Dermatologics | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 73 | 42 | 145 | 93
Ortho Dermatologics | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ortho Dermatologics | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Ortho Dermatologics | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 5 | 5 | 9 | 9
Diversified Products |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 200 | 217 | 427 | 455
Diversified Products | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 164 | 161 | 341 | 343
Diversified Products | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Diversified Products | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 2 | 4 | 4
Diversified Products | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 31 | 55 | 78 | 105
Diversified Products | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 3 | $ (1) | $ 4 | $ 3

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |